|
For immediate release |
26 July 2013 |
("Nanoco" or the "Company")
Director's Dealings
Nanoco Group plc (AIM: NANO) announces that on 25 July 2013, sole legal title in respect of 929,162 ordinary shares of 10 pence each in the Company ("Ordinary Shares") was transferred to Michael Edelman from the Nanoco Employee Benefit Trust (the "EBT"). Previously these Ordinary Shares were jointly owned by Michael Edelman and the EBT.
Therefore, Michael Edelman's total interest in the Company remains unchanged. Dr. Edelman owns 6,988,640 Ordinary Shares, equivalent to 3.3% of the Company's issued share capital.
For further information:
Nanoco |
+ 44 (0) 161 603 7900 |
|
Michael Edelman, Chief Executive Officer |
|
|
Colin White, Chief Financial Officer |
|
|
Canaccord Genuity - Nomad and Joint Broker |
+44 (0) 20 7523 8000 |
|
Simon Bridges |
|
|
Cameron Duncan |
|
|
Liberum Capital - Joint Broker |
+ 44 (0) 20 3100 2000 |
|
Simon Atkinson |
|
|
Richard Bootle |
|
Buchanan |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Fiona Henson / Sophie Cowles |
Notes for editors:
About Nanoco Group plc
Nanoco is a world leader in the development and production of cadmium-free quantum dots for use in multiple applications including LCD displays, lighting and solar cells. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.
Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and business development offices in the USA, Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.
Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocogroup.com.
This information is provided by RNS